149 related articles for article (PubMed ID: 38640424)
1. Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.
Xu J; Abdulsalam Khaleel R; Zaidan HK; Faisal Mutee A; Fahmi Fawy K; Gehlot A; Abbas AH; Arias Gonzáles JL; Amin AH; Ruiz-Balvin MC; Imannezhad S; Bahrami A; Akhavan-Sigari R
Cell Cycle; 2024 Feb; 23(4):405-434. PubMed ID: 38640424
[TBL] [Abstract][Full Text] [Related]
2. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
[TBL] [Abstract][Full Text] [Related]
3. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mosharaf MP; Reza MS; Kibria MK; Ahmed FF; Kabir MH; Hasan S; Mollah MNH
Sci Rep; 2022 Mar; 12(1):4279. PubMed ID: 35277538
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.
Islam MA; Kibria MK; Hossen MB; Reza MS; Tasmia SA; Tuly KF; Mosharof MP; Kabir SR; Kabir MH; Mollah MNH
Sci Rep; 2023 Mar; 13(1):4685. PubMed ID: 36949176
[TBL] [Abstract][Full Text] [Related]
5. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
6. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
8. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
Choi Y; Shin B; Kang K; Park S; Beck BR
Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
[TBL] [Abstract][Full Text] [Related]
9. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
[TBL] [Abstract][Full Text] [Related]
10. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
11. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
12. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
13. Expression of SARS-COV-2 cell receptor gene ACE2 is associated with immunosuppression and metabolic reprogramming in lung adenocarcinoma based on bioinformatics analyses of gene expression profiles.
Uddin MN; Akter R; Li M; Abdelrahman Z
Chem Biol Interact; 2021 Feb; 335():109370. PubMed ID: 33422520
[TBL] [Abstract][Full Text] [Related]
14. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
15. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Trezza A; Iovinelli D; Santucci A; Prischi F; Spiga O
Sci Rep; 2020 Aug; 10(1):13866. PubMed ID: 32807895
[TBL] [Abstract][Full Text] [Related]
16. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
17. A new insight into sex-specific non-coding RNAs and networks in response to SARS-CoV-2.
Askari N; Hadizadeh M; Rashidifar M
Infect Genet Evol; 2022 Jan; 97():105195. PubMed ID: 34954105
[TBL] [Abstract][Full Text] [Related]
18. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.
Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M
Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089
[TBL] [Abstract][Full Text] [Related]
19. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
20. Identification of angiotensin-converting enzyme 2 (ACE2) protein as the potential biomarker in SARS-CoV-2 infection-related lung cancer using computational analyses.
Samad A; Jafar T; Rafi JH
Genomics; 2020 Nov; 112(6):4912-4923. PubMed ID: 32916258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
